◆ 会议时间：2026年3月11-14日
◆ 会议地点：西班牙 巴塞罗那

◆ 会议简介：

2026年第19届糖尿病先进技术与治疗国际会议（ATTD2026）将于2026年3月11-14日在西班牙巴塞罗那举行。国际糖尿病先进技术与治疗大会（ATTD）是一个独特的会议，为临床医生和科学家提供了一个世界级的平台，以介绍、讨论和交流快速发展的糖尿病技术和治疗领域的最新见解宣。ATTD将汇集该领域众多的国际一流专家，共同讨论糖尿病治疗方面的突破性技术创新成果，并展示新的胰岛素类似物、输送系统、泵、葡萄糖传感器、闭环系统等的最新进展。ATTD是与会者了解糖尿病最新研究进展的重要机会，预计有来自世界各地的2500余名代表参会。未经本站许可禁止复制摘录镜像转载本站任何内容-领域国际医学会议网（lingyuint.com）。

The 19th International Conference on Advanced Technologies & Treatments for Diabetes - ATTD 2026

Date:
March 11-14, 2026

Venue:
Barcelona, Spain

摘要征集：

点此提交摘要>>>Submit Abstract>>>

Please read the submission rules before submitting an abstract.

• Abstracts must be submitted online via the website only.
  ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED.
• Presentation Type: Abstracts may be submitted for oral or e-Poster. (Late breaking abstracts can only be submitted for e-Poster.)
• The Scientific Committee will determine whether the abstract will be accepted for presentation (oral/short oral/e-Poster or Read By Title) or declined.
• Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.
• The submission system automatically defines the abstract submitter as a co-author. This cannot be changed after the submission.
  Note if you are not a co-author and are submitting on someone else’s behalf, please use their username and login details to submit the abstract.  
• Publication embargo – All abstracts are under embargo and will be published at the start of the ATTD 2026 conference.

Limitations

• The same person may submit up to 5 abstracts regardless of presenting author.
• The same person may serve as a presenting author on up to 3 abstracts.
• Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by the deadline indicated in the notification email, will be scheduled for presentation and included for publication.
• Submission of an abstract acknowledges your acceptance for the abstract to be published in the official Conference publications.
• The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
• Previously Presented/Published Policy: Abstracts that have been previously presented at another meeting may be submitted. It is preferable that these abstracts contain updates or modifications.
• All accepted abstracts will be published in the peer-reviewed journal Diabetes Technology & Therapeutics, published by Mary Ann Liebert, Inc., Publishers. The Journal is indexed in PubMed.
• The Abstract Submitter grants the Organizers a royalty-free, perpetual, irrevocable nonexclusive license to use, reproduce, publish, translate, distribute, and display the content.
• Abstracts must be submitted in English.
  All abstracts should be submitted and presented in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
• Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.

Instructions for preparation of presentations will be made available on the conference website in due course.

Guidelines for Submission

​Before you begin, please prepare the following information:

• ​Presenting author’s contact details:
  – Full first and family name(s)
  – Email address
  – Affiliation details: department, institution / hospital, city state (if relevant), Country
  – Phone number
• Author and co-authors’ details
• Preferred Presentation type: Oral Presentation / Short Oral Presentation / e-Poster
• Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
• Abstract text – limited to 250 words including acknowledgments. (Please Note: word count is affected when graphs/tables are included).
• Abstract topic– select the abstract topic per the list of topics.
• Images– The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. Note: images don’t affect the word count.
• Abstracts should clearly state:
  Background and aims
  Methods
  Results
  Conclusions 
• Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
• Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
• Submissions may not contain patient names, hospital ID numbers or other identifying information.
• The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted.
• Click on the SUBMIT button at the end of the process in order to save your abstract. You may log in to the system later to make changes to your abstract, up to the submission deadline. After the deadline, abstracts cannot be modified or corrected.
• You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract.
• Please contact us if you have not received confirmation that your abstract has been submitted.
• Please do not submit multiple copies of the same abstract.

Abstract Submitters’ Declaration

During abstract submission you will be asked to confirm that you agree to the following:

1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
2. Submission of the abstract constitutes the consent of all authors to publication (e.g. Conference website, programs, other promotions, etc.)
3. The Abstract Submitter warrants and represents that no part of the information and content provided by him/her (Hereafter: the “Content“) to ATTD 2026 and Kenes International (Hereafter: the “Organizers“), nor the publication of any such Content by the Organizers, on the internet or otherwise infringes any third party rights, including but not limited to  intellectual property rights.
4. The Abstract Submitter grants each of the Organizers the license and right to use, reproduce, publish, translate, distribute, and display the Content or any part thereof, in any manner and on any platform or media whatsoever, in each Organizer’s absolute discretion, on a royalty-free, perpetual, irrevocable nonexclusive basis.
5. I herewith confirm that the contact details saved in this system are those of the presenting author, who will be notified about the status of the abstract. The presenting author is responsible for informing the other authors about the status of the abstract. The submitting author may request to be copied on abstract correspondence.
6. I understand that the presenting author must be a registered participant.
7. The Organizers reserve the right to remove from publication and/or presentation an abstract which does not comply with the above.
8. I understand that I must select a specific Theme, Topic and/or Sub-Topic for my abstract allocation.  Although the Committee will work hard to honor this selection, this cannot be guaranteed.  The Committee reserves the right to change the Theme, Topic or Sub-Topic under which the abstract was originally submitted.
9. I confirm to have received the consent of all authors for the processing of their contact details by Kenes and the Organizers.

Dear Colleagues

It is our pleasure to welcome you to the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2026) taking place at the fascinating city of Barcelona, on March 11-14, 2026.

Join us at ATTD 2026, the premier international platform where a diverse community – clinicians, diabetes care providers, researchers, industry, startups, investors, reimbursement authorities, and regulators – collaborates to drive rapid progress in diabetes care.

The conference program features presentations and discussions led by distinguished professionals, covering a wide spectrum of innovations from artificial intelligence and glucose technology to novel therapies and prevention strategies.

We look forward to your contributions and active participation, which will be instrumental in making ATTD 2026 a high-impact and unforgettable occasion.

See you in Barcelona!

Yours sincerely,

Professor Moshe Phillip & Professor Tadej Battelino
Conference Chairpersons

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。